Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
- 2013
Ceftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright 2013 Elsevier Inc. All rights reserved.
English
0732-8893
*Anti-Bacterial Agents/tu [Therapeutic Use]
*Cephalosporins/tu [Therapeutic Use]
*Community-Acquired Infections/dt [Drug Therapy]
*Pneumonia, Pneumococcal/dt [Drug Therapy]
Aged
Aged, 80 and over
Bacteremia/dt [Drug Therapy]
Bacteremia/mi [Microbiology]
Ceftriaxone/tu [Therapeutic Use]
Community-Acquired Infections/mi [Microbiology]
Female
Humans
Logistic Models
Male
Microbial Sensitivity Tests
Middle Aged
Odds Ratio
Pneumonia, Pneumococcal/mi [Microbiology]
Retrospective Studies
Treatment Outcome
MedStar Washington Hospital Center
Medicine/Pulmonary-Critical Care
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Ceftaroline fosamil resulted in higher cure rates than ceftriaxone in patients with community-acquired bacterial pneumonia in 2 randomized trials (FOCUS 1 and FOCUS 2). The present analysis examines the subgroup of patients with Streptococcus pneumoniae infection to determine whether the apparent difference in cure rates persists after adjusting for potential covariates. We retrospectively pooled subjects with S. pneumoniae isolated at baseline in the original studies and employed logistic regression to evaluate the independent relationship between clinical cure and treatment with ceftaroline. Covariates evaluated included demographics, severity of illness, bacteremia, and pathogen characteristics. The final cohort included 139 subjects (69 ceftaroline, 70 ceftriaxone). Unadjusted cure rates were 85.5% and 68.6% (P = 0.009) in the ceftaroline and ceftriaxone groups, respectively. After logistic regression, ceftaroline remained associated with higher cure rates. Our findings indicate that ceftaroline may result in improved outcomes of S. pneumoniae pneumonia. Formal clinical trials are warranted to confirm this hypothesis. Copyright 2013 Elsevier Inc. All rights reserved.
English
0732-8893
*Anti-Bacterial Agents/tu [Therapeutic Use]
*Cephalosporins/tu [Therapeutic Use]
*Community-Acquired Infections/dt [Drug Therapy]
*Pneumonia, Pneumococcal/dt [Drug Therapy]
Aged
Aged, 80 and over
Bacteremia/dt [Drug Therapy]
Bacteremia/mi [Microbiology]
Ceftriaxone/tu [Therapeutic Use]
Community-Acquired Infections/mi [Microbiology]
Female
Humans
Logistic Models
Male
Microbial Sensitivity Tests
Middle Aged
Odds Ratio
Pneumonia, Pneumococcal/mi [Microbiology]
Retrospective Studies
Treatment Outcome
MedStar Washington Hospital Center
Medicine/Pulmonary-Critical Care
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't